Thermo Fisher Scientific Inc. $TMO Shares Acquired by Focus Partners Wealth

Key Points

• Focus Partners Wealth increased its stake in Thermo Fisher Scientific by 6.0% during Q1, now holding 219,621 shares worth approximately $109 million.
• Thermo Fisher reported a $5.36 EPS, surpassing expectations of $5.22, and recorded a revenue of $10.86 billion in its latest quarterly earnings.
• The company declared a quarterly dividend of $0.43 per share, with an annualized yield of 0.4%, payable on October 15th.

Focus Partners Wealth grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 219,621 shares of the medical research company's stock after buying an additional 12,452 shares during the period. Focus Partners Wealth owned 0.06% of Thermo Fisher Scientific worth $109,284,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TMO. Flaharty Asset Management LLC bought a new position in Thermo Fisher Scientific during the 1st quarter valued at about $68,000. Integrity Alliance LLC. raised its stake in Thermo Fisher Scientific by 735.7% during the 1st quarter. Integrity Alliance LLC. now owns 8,867 shares of the medical research company's stock worth $4,412,000 after acquiring an additional 7,806 shares during the period. Ransom Advisory Ltd purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $2,337,000. Anchor Investment Management LLC grew its holdings in Thermo Fisher Scientific by 1.4% during the 1st quarter. Anchor Investment Management LLC now owns 11,622 shares of the medical research company's stock valued at $5,783,000 after buying an additional 157 shares in the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co grew its holdings in shares of Thermo Fisher Scientific by 5.3% in the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock valued at $33,488,000 after purchasing an additional 3,400 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last 90 days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 2.4%

Shares of NYSE TMO traded down $11.93 during mid-day trading on Friday, reaching $479.48. 1,543,232 shares of the company's stock were exchanged, compared to its average volume of 1,555,589. The company's 50-day moving average is $466.86 and its 200-day moving average is $451.65. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The firm has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TMO shares. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird lifted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Seventeen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.